BIO vs CRL

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 09, 2026

BIO

42.0
AI Score
VS
BIO Wins

CRL

38.3
AI Score

Investment Advisor Scores

BIO

42score
Recommendation
HOLD

CRL

38score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric BIO CRL Winner
Revenue 2.00B 1.24B CRL
Net Income -16.32M -155.70M CRL
Net Margin -0.8% -12.5% CRL
Operating Income 239.78M 106.70M CRL
ROE -0.6% -2.2% CRL
ROA -0.2% -1.5% CRL
Total Assets 7.53B 10.25B BIO
Cash 192.03M 517.00M BIO
Current Ratio 1.35 3.14 BIO

Relative Price Performance (Last 90 Days)

BIO 1M: +2.8% · 3M: +27.3% CRL 1M: -2.7% · 3M: +47.1%

Current Technical Phase

BIO

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (11.2% over 20 days), RSI 54

RSI (14): 53.7 · Price: $372.22

CRL

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 50

RSI (14): 49.9 · Price: $276.61

Fundamentals Snapshot

Metric BIO CRL
Market Cap
Forward P/E 36.8 21.5
Trailing P/E 45.9
Revenue (TTM)
Revenue Growth 0.0% 0.0%
Gross Margin 0.5% 0.3%
Operating Margin 0.1% 0.2%
EPS 8.21 -4.76
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, BIO is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.